🔥🐔 BizChicken 🐔🔥

Learn About the Corporations Around You

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

TScan Therapeutics, Inc.

TScan Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

T cell receptor-engineered T cell therapies

TScan Therapeutics, Inc. is a preclinical-stage biopharmaceutical company that develops T cell receptor-engineered T cell therapies for cancer treatment. It is working on therapies for hematologic malignancies and solid tumors, as well as vaccines for infectious diseases like SARS-CoV-2.

Tags: Novartis collaboration, SARS-CoV-2, T cell therapies, biopharmaceutical, cancer treatment, hematologic malignancies, infectious diseases, solid tumors

Website

About | About | Management | Directors | About | About | Contact | Careers | Careers | Careers | About | About

Symbol: TCRX

Recent Price: $3.00

Industry: Biotechnology

CEO: Dr. Gavin MacBeath Ph.D.

Sector: Healthcare

Employees: 175

Address: 830 Winter Street, Waltham, MA 02451

Phone: 857 399 9500

Leadership

  • Stephen Biggar, M.D., Ph.D., Partner at Baker Bros. Advisors LP
  • Katina Dorton, J.D., M.B.A., CFO of Nodthera
  • Gabriela Gruia, M.D., Chief Development Officer at Ichnos Sciences
  • Barbara Klencke, M.D., Former Chief Medical Officer and Chief Development Officer of Sierra Oncology Inc.
  • Gavin MacBeath, Ph.D., CEO of TSCAN
  • Garry Nicholson, Former President of Pfizer Oncology
  • R. Keith Woods, Former Chief Operating Officer of argenx

Last updated: 2024-12-31